Renhe Pharmacy To Acquire Jiangxi Kangmei Healthcare And Jiangxi Yaodu Renhe Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
Renhe Pharmacy will issue 60-90 million private shares, priced at least RMB 6.74 per share, to 10 or fewer potential buyers. The raised fund will be used to acquire the firm's controlling shareholder Renhe (Group) Development's 100 percent stake in both Jiangxi Kangmei Healthcare and Jiangxi Yaodu Renhe Pharmaceutical. Renhe Pharmacy expresses that the acquisition will reduce the number of related deals, thus strengthening its independence in purchase, production and sales. After the acquisition, the company will add 15 pharmaceutical formulations and nine food formulations as well as increase production capacity in health products and external sterilizing items. It will also introduce new organizational investors to further improve its legal and management structure. (Click here for more - Chinese Language)
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.